Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | MT-CO2 | P00403 | 2/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.48 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | APAF1 | O14727 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17884573 | 0.88 | DDB1 (0.56) | ALDH1A1MT-CO2ALOX5DDB1CRBN | |
| SCHEMBL20556483 | 0.88 | DDB1 (0.54) | ALDH1A1MT-CO2ALOX5DDB1CRBN | |
| SCHEMBL24294812 | 0.88 | ALDH1A1 (0.46) | ALDH1A1MT-CO2ALOX5DDB1CRBN | |
| SCHEMBL17169711 | 0.87 | ALDH1A1 (0.60) | ALDH1A1MT-CO2ALOX5CYP1A2OPRM1 | |
| SCHEMBL29357653 | 0.87 | DDB1 (0.57) | ALDH1A1MT-CO2ALOX5DDB1CRBN | |
| SCHEMBL2172756 | 0.86 | GAA (0.54) | ALDH1A1CYP1A2CHRM2OPRM1DDB1 | |
| SCHEMBL25059015 | 0.84 | ALDH1A1 (0.53) | ALDH1A1MT-CO2ALOX5CYP1A2CASP3 | |
| SCHEMBL20841251 | 0.83 | DDB1 (0.54) | ALDH1A1MT-CO2ALOX5DDB1CRBN | |
| SCHEMBL17873805 | 0.83 | DDB1 (0.60) | ALDH1A1MT-CO2ALOX5DDB1CRBN | |
| SCHEMBL17873792 | 0.83 | DDB1 (0.51) | ALDH1A1MT-CO2ALOX5DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | YALE UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | YALE UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20150291562-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2015-10-15 | — | — | US | disclosed |
| US-20090156641-A1 | INHIBITION OF CYCLOOXYGENASE-2 ACTIVITY | CELGENE CORPORATION | 2009-06-18 | — | — | US | disclosed |
| US-20060199819-A1 | Inhibition of cyclooxygenase-2 activity | CELGENE CORPORATION | 2006-09-07 | — | — | US | disclosed |
| US-20040077686-A1 | Inhibition of cyclooxygenase-2 activity | CORNELL RESEARCH FOUNDATION, INC. | 2004-04-22 | — | — | US | disclosed |
| EP-1272189-A4 | INHIBITION OF CYCLOOXYGENASE-2 ACTIVITY | CELGENE CORP (US) | 2004-01-14 | — | — | EP | disclosed |
| CN-1420776-A | Inhibition of cyclooxygenase-2 activity | CELGENE CORP (US) | 2003-05-28 | — | — | CN | disclosed |
| EP-1272189-A1 | INHIBITION OF CYCLOOXYGENASE-2 ACTIVITY | CELGENE CORPORATION (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20020022627-A1 | Inhibition of cyclooxygenase-2activity | CORNELL RESEARCH FOUNDATION, INC. | 2002-02-21 | — | — | US | disclosed |
| WO-2001074362-A1 | INHIBITION OF CYCLOOXYGENASE-2 ACTIVITY | CELGENE CORPORATION (US) | 2001-10-11 | — | — | WO | disclosed |
| US-5385901-A | Treating patients with 3-phthalimido-2,6-dioxopiperidine for toxic symptoms of septic shock, cachexia and HIV infection by inhibiting excessive production of tumor necrosis factor alpha | THE ROCKEFELLER UNIVERSITY (US) | 1995-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | ALDH1A1 3804/4885MT-CO2 3294/4885ALOX5 4865/4885 |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | ALDH1A1 798/4885MT-CO2 3374/4885ALOX5 4011/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | ALDH1A1 2211/4885MT-CO2 4728/4885ALOX5 4680/4885 |
| US-20020022627-A1 | Inhibition of cyclooxygenase-2activity | PTGS2, PTGES2, PTGS1 | ALDH1A1 637/4885MT-CO2 263/4885ALOX5 35/4885 |
| US-20090156641-A1 | INHIBITION OF CYCLOOXYGENASE-2 ACTIVITY | PTGS2, PTGS1, PTGES2 | ALDH1A1 617/4885MT-CO2 339/4885ALOX5 29/4885 |
| US-20150291562-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | CRBN, MDM2, UBE2N | ALDH1A1 3412/4885MT-CO2 4176/4885ALOX5 4744/4885 |
| US-20040077686-A1 | Inhibition of cyclooxygenase-2 activity | PTGS2, PTGS1, PTGES2 | ALDH1A1 617/4885MT-CO2 339/4885ALOX5 29/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | ALDH1A1 3688/4885MT-CO2 3923/4885ALOX5 4182/4885 |
| US-20060199819-A1 | Inhibition of cyclooxygenase-2 activity | PTGS2, PTGS1, PTGES2 | ALDH1A1 617/4885MT-CO2 339/4885ALOX5 29/4885 |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | CRBN, MDM2, UBE2N | ALDH1A1 3412/4885MT-CO2 4176/4885ALOX5 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.